Windward Bio

Windward Bio develops monoclonal antibodies for advanced immunological diseases.

Latest funding

$200M Series A · January 10, 2025

Led by Blue Owl Capital · Source: globenewswire.com

All 2 rounds ↓

Website: windwardbio.com.

LinkedIn: linkedin.com.

Category: Health and bio.

Sectors: Biopharma, Biotechnology, Clinical Trials, Health Care, Life Science.

Stage: Series A.

Based in: Basel, Switzerland.

Last round: May 5, 2026 · 191 days ago.

Headcount: 11–50 employees.

On Recent Funding since: Nov 6, 2026.

Signals

Website registeredJan 30, 2020 (6 years old)

Funding rounds

May 5, 2026
Round · amount undisclosed
Source: fundraisingfox.com
January 10, 2025
Series A · $200M
BBlue Owl Capital (lead), NNovo Holdings (lead), OOrbiMed (lead), OOmega Funds, PPivotal bioVenture Partners, QQiming Venture Partners, QQuan Capital, RRTW Investments, SSR One
Source: globenewswire.com
January 30, 2020
Website created

Founders and team

LS
Luca Santarelli Founder
CD
Claudia D’Augusta Chief Financial Officer
JS
Jeffrey Stavenhagen Chief Scientific Officer
KH
Kevin Harris Chief Operating Officer
OK
Omar Khwaja Chief Medical Officer
SA
Scott Applebaum Chief Legal & Corporate Development Officer

Investors

Companies like Windward Bio

DDren Bio$350M Series B+ · Oct 2026
UUmlaut.Bio$3.46M Pre Seed · Feb 2026
GGranite Bio$30M Series A · Apr 2025
MMerida Biosciences$120M Series A · May 2025
AAnaveon$120M Series B+ · Dec 2021

Other companies backed by Blue Owl Capital

CCAIS$170M Series B+ · Jul 2026
AAlphaSense$350M Series B+ · Jun 2026
AAllica$155M Series B+ · Feb 2026
VVestwell$385M Series B+ · Feb 2026
TTorl Bio$96M Series B+ · Oct 2025
NNeuron23$97M Series B+ · Jun 2025

Blue Owl Capital portfolio →

Sources and API

Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/windward-bio (get a free API key).